Beyondspring received FDA Fast Track designation for Plinabulin in treating post-ICI non-squamous NSCLC and announced a strategic transaction to support the global Phase 3 Dublin-4 trial leading to an interim analysis.

Observed price moves

• BYSI+11.40%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.